SQZ TILs / STEMCELL Technologies - LARVOL DELTA

STEMCELL Technologies Announces Successful Completion of Asset Purchase Agreement with SQZ Biotechnologies Company [Google translation] (Businesswire) - "STEMCELL Technologies is pleased to announce that it has acquired substantially all of the assets of SQZ Biotechnologies Company...This transaction, which was approved today by SQZ shareholders, marks another important milestone for STEMCELL, Canada's largest biotechnology company....Once the SQZ transaction was approved, STEMCELL was able to acquire substantially all of SQZ's assets, including its entire portfolio of more than 400 patents and trademarks, other intellectual property rights such as copyrights and trade secrets, proprietary equipment and its master license from the Massachusetts Institute of Technology."

M&A • Cervical Cancer • CNS Disorders • Gynecologic Cancers • Head and Neck Cancer • Oncology • Parkinson's Disease • Solid Tumor

SQZ Biotechnologies Presents Preclinical SQZ TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies (Businesswire) - "SQZ Biotechnologies Company...presented preclinical data supporting that tumor infiltrating lymphocytes (TILs) engineered with membrane-bound cytokines IL-2 (mbIL-2) and IL-12 (mbIL-12) may eliminate the need for the high-dose, systemic IL-2 and lymphodepleting preconditioning used with current TIL therapies. SQZ^® TILs showed the ability to induce desirable cytokine signaling for more than 48 hours, which is comparable to the duration of exogenous IL-2 support in current TIL therapies. SQZ^® TILs also demonstrated improved killing of donor-matched tumor cells, upregulated markers associated with central memory T cells, and persistence in vivo. The data was presented today at the European Society for Medical Oncology (ESMO) Congress 2022."

Preclinical • Oncology • Solid Tumor